UCIBIO, Departamento Ciências da Vida NOVA School of Science and Technology, Caparica
UCIBIO, Departamento Ciências da Vida
NOVA School of Science and Technology, Caparica
2829-516 Lisbon, Portugal
CellmAbs, co-founder and CTO
p.videira@fct.unl.pt
Paula A. Videira is the leader of the Glycoimmunology Research Group at UCIBIO and Associate Professor in Immunology and Glycobiology at NOVA School of Science and Technology, Universidade NOVA de Lisboa (NOVA-FCT, Portugal). Prof. Videira is highly motivated to comprehend the intricate roles of glycans in disease, and dedicated to translating Glycosciences into innovative immunotherapies. She co-directs CDG&Allies and, in 2019, co-founded CellmAbs, a successful spin-off focused on developing glycan-based immunotherapies for oncology. In 2024, CellmAbs clsoed a historic negotiation with a major pharmaceutical company to advance into clinical trials. She has also co-founded Valvian, a novel biopharmaceutical company centered on novel AI-driven immune therapies. Her academic background includes a degree in Biochemistry, a MSc and PhD in Biotechnology, and an Habilitation in Biology from NOVA FCT. She was an Erasmus fellow at Bergen University (Norway, 1994-1995), a research fellow at CERMAV (France, 1999), and a post-doctoral researcher at IST (Portugal, 2002-2005). Her leadership in Glycoimmunology developed as an Assistant Professor at NOVA Medical School (2005-2015) and at NOVA FCT (2015-2023). She has established a solid international network, coordinating 18 projects, including GLYCOTwinning and ProDGNE. She has also held visiting professorships at Bologna University (Italy, 2007), Harvard Medical School as an EMBO and Fulbright Fellow (USA, 2011 and 2013), and at the Federal University of Ceará (Brazil, 2014-2023).
